Search results for " disease progression"

showing 10 items of 81 documents

IMPAIRED ALLOCENTRIC SPATIAL MEMORY UNDERLYNG TOPOGRAPHICAL DISORIENTATION

2006

The cognitive processes supporting spatial navigation are considered in the context of a patient (CF) with possible very early Alzheimer's disease who presents with topographical disorientation. Her verbal memory and her recognition memory for unknown buildings, landmarks and outdoor scenes was intact, although she showed an impairment in face processing. By contrast, her navigational ability, quantitatively assessed within a small virtual reality (VR) town, was significantly impaired. Interestingly, she showed a selective impairment in a VR object-location memory test whenever her viewpoint was shifted between presentation and test, but not when tested from the same viewpoint. We suggest t…

Activities of Daily Living/psychology Aged Alzheimer Disease/diagnosis Alzheimer Disease/physiopathology Alzheimer Disease/psychology Animals Disability Evaluation Disease Progression Early Diagnosis Female Hippocampus/pathology Hippocampus/physiopathology Humans Memory/physiology Memory Disorders/diagnosis Memory Disorders/physiopathology Memory Disorders/psychology Middle Aged Models Neurological Neuropsychological Tests Orientation/physiology Space Perception/physiology Verbal Behavior/physiologySettore M-PSI/02 - Psicobiologia E Psicologia Fisiologica
researchProduct

Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study

2016

Objective The biological heterogeneity of hepatocellular carcinoma (HCC) makes prognosis difficult. We translate the results of a genome-wide high-throughput analysis into a tool that accurately predicts at presentation tumour growth and survival of patients with HCC.Design Ultrasound surveillance identified HCC in 78 (training set) and 54 (validation set) consecutive patients with cirrhosis. Patients underwent two CT scans 6 weeks apart (no treatment in-between) to determine tumour volumes (V-0 and V-1) and calculate HCC doubling time. Baseline-paired HCC and surrounding tissue biopsies for microarray study (Agilent Whole Human Genome Oligo Microarrays) were also obtained. Predictors of su…

AdultMale0301 basic medicinemedicine.medical_specialtyTime FactorsCarcinoma HepatocellularTime FactorMicroarrayHepatocellular carcinomamolecular carcinogenesisGastroenterologyliver imagingHEPATOCELLULAR CARCINOMA; LIVER IMAGING; MOLECULAR CARCINOGENESIS; MOLECULAR ONCOLOGY; Adult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization Pathologic; Prospective Studies; Survival Rate; Time Factors; Tumor Burden; Medicine (all); Gastroenterology03 medical and health sciencesmolecular oncology0302 clinical medicineHepatocellular carcinoma liver imaging molecular carcinogenesis molecular oncologyInternal medicinemedicineCarcinomaHumansDoubling timeProspective StudiesProspective cohort studySurvival rateAgedAged 80 and overNeovascularization Pathologicbusiness.industryProportional hazards modelLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseTumor BurdenSurvival RateProspective Studie030104 developmental biologyQuartileLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaDisease ProgressionFemalebusinessHumanGut
researchProduct

The neuropsychology of variant CJD: a comparative study with inherited and sporadic forms of prion disease.

2005

Objective: To assess cognitive function in variant Creutzfeldt-Jakob disease (vCJD). We describe the neuropsychological profiles of 10 cases and compare these data with cross sectional data obtained from patients with histologically confirmed sporadic CJD and cases with inherited prion disease with confirmed mutations in the prion protein gene. Methods: Patients referred to the Specialist Cognitive Disorders Clinic at the National Hospital for Neurology and Neurosurgery and the National Prion Clinic at St Mary's Hospital, London for further investigation of suspected CJD were recruited into the study. The neuropsychological test battery evaluated general intelligence, visual and verbal memo…

AdultMalePaperPediatricsmedicine.medical_specialtyPrionsanimal diseasesDNA Mutational AnalysisNeuropsychological TestsCreutzfeldt-Jakob SyndromePrion DiseasesNational Prion Clinicmental disordersmedicineDementiaHumansCognitive declinePsychiatrymedicine.diagnostic_testSettore M-PSI/02 - Psicobiologia E Psicologia Fisiologicabusiness.industryNeuropsychologyNeuropsychological testCreutzfeldt-Jakob SyndromeMiddle Agedmedicine.diseasenervous system diseasesPsychiatry and Mental healthCross-Sectional StudiesAdult Cognition Disorders/etiology Creutzfeldt-Jakob Syndrome/complications Creutzfeldt-Jakob Syndrome/genetics Creutzfeldt-Jakob Syndrome/psychology Cross-Sectional Studies DNA Mutational Analysis Disease Progression Female Humans Male Middle Aged Neuropsychological Tests Prion Diseases/genetics Prion Diseases/psychology Prions/genetics Visual PerceptionDisease ProgressionVisual PerceptionSurgeryFemaleNeurology (clinical)Verbal memorybusinessCognition DisordersExecutive dysfunctionJournal of neurology, neurosurgery, and psychiatry
researchProduct

Non respiratory symptoms in asthma as possible predictors of exacerbations

2015

Anxiety 34 37 36 Headache 28 23 26 Abdominal pain 1 3 2 Weakness 13 4 9 Depression 5 0 3 Impaired sleep 4 8 7 Nicturia 7 0 5 Chest pain 11 7 9 Excitement 13 6 10 Nonlocalized pain 4 4 4 Hunger 3 4 3 Lack of appetite 5 5 5 Fever 1 3 2 Nausea 1 5 4 Urticaria 3 0 2 Palpitation 28 23 26 Heartburn 11 7 10 Generalized itching 22 30 25 Non respiratory symptoms in asthma as possible predictors of exacerbations Gennaro Liccardi, MD, Gennaro Baldi, MD, Adriano Berra, MD, Emanuela Carpentieri, MD, Marina Cutajar, MD, Maria D’Amato, MD, Mario Del Donno, MD, Bruno Del Prato, MD, Ilenia Folletti, MD, Federica Gani, MD, Domenico Gargano, MD, Domenico Giannattasio, MD, Michele Giovannini, MD, Antonio Infan…

AdultMalemedicine.medical_specialtyAdolescentPrognosiSettore MED/10 - Malattie Dell'Apparato RespiratorioAutonomic Nervous SystemYoung AdultAdolescent; Adult; Aged; Anxiety Disorders; Asthma; Autonomic Nervous System; Child; Cross-Sectional Studies; Disease Progression; Female; Humans; Italy; Male; Middle Aged; Prognosis; Young AdultmedicineImmunology and AllergyHumansPsychiatryChildAgedAdolescent; Adult; Aged; Anxiety Disorders; Asthma; Autonomic Nervous System; Child; Cross-Sectional Studies; Disease Progression; Female; Humans; Italy; Male; Middle Aged; Prognosis; Young Adult; Immunology and Allergy; Medicine (all)Cross-Sectional Studiebusiness.industryMedicine (all)Disease progressionMiddle AgedPrognosisAnxiety DisordersAsthmaCross-Sectional StudiesItalyDisease ProgressionFemalebusinessAnxiety DisorderHuman
researchProduct

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

2015

Background— Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results— We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of med…

Angiotensin receptorVascular damage Radboud Institute for Health Sciences [Radboudumc 16]receptorsTetrazolesheart failureAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateSacubitrilAngiotensin; Heart failure; Neprilysin; Receptors; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Double-Blind Method; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Disease Progression; Medicine (all); Cardiology and Cardiovascular Medicine; Physiology (medical)AngiotensinEnalaprilRisk FactorsEnalapril/therapeutic useNatriuretic Peptide BrainHeart Failure/bloodSurvivorsReceptorNeprilysinAminobutyrates: Systèmes cardiovasculaire & respiratoire [D03] [Sciences de la santé humaine]Troponin/bloodTroponinAngiotensin Receptor Antagonists/therapeutic useDrug CombinationsAngiotensin-Converting Enzyme Inhibitors/therapeutic useTreatment OutcomeTetrazoles/therapeutic useCardiologyDisease ProgressionValsartanNeprilysinHeart Failure/blood/drug therapy/physiopathologyCardiology and Cardiovascular Medicinemedicine.drugReceptormedicine.medical_specialtyHeart failureneprilysinAngiotensin Receptor Antagonistsreceptors angiotensinDouble-Blind MethodPhysiology (medical)Internal medicineRenin–angiotensin systemmedicineHumansheart failure neprilysin receptors angiotensinEnalaprilbusiness.industryBiphenyl CompoundsStroke Volumemedicine.diseasePeptide FragmentsEndocrinologyAminobutyrates/therapeutic useStroke Volume/physiologyHeart failureNatriuretic Peptide Brain/blood: Cardiovascular & respiratory systems [D03] [Human health sciences]businessNeprilysin/antagonists & inhibitorsPeptide Fragments/bloodSacubitril ValsartanBiomarkersBiomarkers/blood
researchProduct

The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?

2015

Background: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body mass index (BMI), fasting blood glucose level (FBG) and blood pressure (BP) levels and the outcome of patients treated with everolimus for mRCC. Methods: 177 patients were included in this retrospective analysis. Time to progression (TTP), clinical benefit (CB) and overall survival (OS) were evaluated. Results: Basal BMI was significantly higher in patients who experienced a CB (p=0,0145). C, T an…

Blood Glucoselcsh:MedicineBlood Pressureurologic and male genital diseasesTriglycerideBody Mass IndexAntineoplastic Agentchemistry.chemical_compoundRetrospective StudieRenal cell carcinomalcsh:ScienceMultidisciplinaryKidney NeoplasmKidney NeoplasmsSurvival RateEverolimuCholesterolDisease ProgressionHumanmedicine.drugResearch ArticleAdultmedicine.medical_specialtyAdolescentUrologyBlood sugarAntineoplastic AgentsYoung AdultInternal medicinemedicineCarcinomaHumansEverolimusCarcinoma Renal CellTriglyceridesNeoplasm StagingRetrospective StudiesBiochemistry Genetics and Molecular Biology (all)EverolimusCholesterolbusiness.industrylcsh:RCarcinomaRenal CellAdolescent; Adult; Antineoplastic Agents; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Carcinoma Renal Cell; Cholesterol; Disease Progression; Everolimus; Humans; Kidney Neoplasms; Lipid Metabolism; Neoplasm Staging; Retrospective Studies; Survival Rate; Triglycerides; Young Adult; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Lipid metabolismBiomarkermedicine.diseaseLipid Metabolismrenal; carcinomaBlood pressureEndocrinologyAgricultural and Biological Sciences (all)chemistryPharmacodynamicslcsh:QbusinessBiomarkersPloS one
researchProduct

Genetic evolution of T-cell resistance in the course of melanoma progression

2014

Abstract Purpose: CD8+ T lymphocytes can kill autologous melanoma cells, but their activity is impaired when poorly immunogenic tumor phenotypes evolve in the course of disease progression. Here, we analyzed three consecutive melanoma lesions obtained within one year of developing stage IV disease for their recognition by autologous T cells. Experimental Design: One skin (Ma-Mel-48a) and two lymph node (Ma-Mel-48b, Ma-Mel-48c) metastases were analyzed for T-cell infiltration. Melanoma cell lines established from the respective lesions were characterized, determining the T-cell–stimulatory capacity, expression of surface molecules involved in T-cell activation, and specific genetic alteratio…

Cancer ResearchB7 Antigensmedicine.medical_treatmentMedizinGene ExpressionT-Lymphocyte Subsetshemic and lymphatic diseasesCluster AnalysisLymphocytesNeoplasm MetastasisLymph nodeMelanomaTumorImmunogenicityMelanomaSingle Nucleotidemedicine.anatomical_structurePhenotypeButorphanolOncologyDisease ProgressionCytokinesEvolutionT cellHuman leukocyte antigenBiologyPolymorphism Single NucleotideArticleCell LineEvolution MolecularLymphocytes Tumor-InfiltratingCell Line TumormedicineHumansGenetic Predisposition to DiseaseTumor-InfiltratingAllelePolymorphismneoplasmsAllelesNeoplasm StagingHistocompatibility Antigens Class IMolecularImmunotherapymedicine.diseaseAlleles; B7 Antigens; Butorphanol; Cell Line Tumor; Cluster Analysis; Cytokines; Disease Progression; Gene Expression; Genetic Predisposition to Disease; Histocompatibility Antigens Class I; Humans; Lymphocytes Tumor-Infiltrating; Melanoma; Mutation; Neoplasm Metastasis; Neoplasm Staging; Phenotype; Polymorphism Single Nucleotide; T-Lymphocyte Subsets; beta 2-Microglobulin; Evolution Molecular; Oncology; Cancer ResearchImmunologyMutationbeta 2-MicroglobulinCD8
researchProduct

The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung …

2014

Lower respiratory tract infections (LRTIs), including pneumonia and acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD), are among the most common diagnoses in both outpatient and inpatient settings. Due to the burden of LRTIs healthcare providers must adopt practices focused on improving outcomes with the aim to reduce treatment failure and antibiotic resistances. Moreover, the role of acute and chronic infection in the pathogenesis of COPD has received considerable attention, since chronic infection can contribute to airways inflammation and COPD progression. This review discusses the role of cefditoren for the treatment of LRTIs, compared with the definition of "appropria…

Chronic ObstructiveDose-Response Relationship DrugDrug ResistanceBacterialMicrobial Sensitivity TestsPneumoniaSettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-Bacterial AgentsCephalosporinsCommunity-Acquired InfectionsDose-Response RelationshipPulmonary DiseasePulmonary Disease Chronic ObstructiveDrug Resistance Multiple BacterialPneumonia BacterialDisease ProgressionHumansAnti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Disease Eradication; Disease Progression; Dose-Response Relationship Drug; Drug Resistance Multiple Bacterial; Humans; Microbial Sensitivity Tests; Pneumonia Bacterial; Pulmonary Disease Chronic ObstructiveDisease EradicationDrugantibiotics outpatients COPDMultiple
researchProduct

Emergence of Aspergillus fumigatus azole resistance in azole-naïve patients with chronic obstructive pulmonary disease and their homes.

2017

Azole-resistant Aspergillus fumigatus (ARAF) has been reported in patients with chronic obstructive pulmonary disease (COPD) but has not been specifically assessed so far. Here, we evaluated ARAF prevalence in azole-naïve COPD patients and their homes, and assessed whether CYP51A mutations were similar in clinical and environmental reservoirs. Sixty respiratory samples from 41 COPD patients with acute exacerbation and environmental samples from 36 of these patient's homes were prospectively collected. A. fumigatus was detected in respiratory samples from 11 of 41 patients (27%) and in 15 of 36 domiciles (42%). Cyp51A sequencing and selection on itraconazole medium of clinical (n = 68) and e…

Drug Resistance Fungal -- genetics0301 basic medicineAzolesMaleAntifungal AgentsExacerbationMESH: Fungal Proteins/isolation & purification[SDV]Life Sciences [q-bio]Colony Count MicrobialAspergillus fumigatusMESH: Aspergillus fumigatus/drug effectsMESH: Cytochrome P-450 Enzyme System/drug effectsMESH: GenotypePulmonary Disease Chronic ObstructivedwellingCytochrome P-450 Enzyme SystemGenotypePulmonary Disease Chronic Obstructive -- microbiologyPrevalenceProspective Studieschemistry.chemical_classificationMESH: AgedCOPDAzole-resistanceMESH: Middle AgedbiologyMESH: Drug Resistance Fungal/geneticsMold environmental exposureSciences bio-médicales et agricolesMiddle Aged3. Good healthMESH: Pulmonary Disease Chronic Obstructive/microbiology*MESH: Housing[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyAir Pollution IndoorAcute DiseaseDisease ProgressionMESH: Acute DiseaseMESH: Cytochrome P-450 Enzyme System/isolation & purificationMESH: Disease ProgressionFemalemedicine.drugmedicine.medical_specialtyEnvironmental EngineeringGenotypeItraconazoleMESH: Fungal Proteins/drug effects030106 microbiologyAspergillus fumigatus -- drug effects -- genetics -- isolation & purificationMESH: Azoles/pharmacology*Fungal Proteins -- drug effects -- isolation & purificationchronic obstructive pulmonary diseaseMicrobiologyFungal Proteins03 medical and health sciencesazole resistanceMESH: Air Pollution Indoor/analysis*Drug Resistance FungalInternal medicinemedicineCOPDHumansMESH: Aspergillus fumigatus/geneticsDwellingMESH: Colony Count MicrobialMESH: PrevalenceAgedAspergillusMESH: HumansAspergillus fumigatusAzoles -- pharmacologyelectrostatic dust collectorPublic Health Environmental and Occupational Healthmold environmental exposureElectrostatic dust collectorBuilding and Constructionmedicine.diseasebiology.organism_classificationMESH: MaleMESH: Prospective StudieschemistryCytochrome P-450 Enzyme System -- drug effects -- isolation & purificationHousingAzoleARAFMESH: Aspergillus fumigatus/isolation & purification*Antifungal Agents -- pharmacologyMESH: Antifungal Agents/pharmacology*MESH: FemaleAir Pollution Indoor -- analysisIndoor air
researchProduct

Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab The…

2022

N/A

Dupilumab TherapyAntibodies Monoclonal Humanized; Disease Progression; Humans; Treatment Outcome; COVID-19; Dermatitis AtopicDermatitisAtopic dermatitis.DermatologyDupilumabAntibodies Monoclonal HumanizedAntibodiesAtopicDermatitis AtopicSettore MED/35MonoclonalImmunology and AllergyHumanshumanHumanizedAtopic dermatitistreatment outcome Antibodies Monoclonal HumanizedCOVID-19Treatment OutcomeCOVID-19 Dupilumab Therapydisease exacerbationDisease ProgressionSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanmonoclonal antibody atopic dermatiti
researchProduct